<?xml version='1.0' encoding='utf-8'?>
<document id="16416302"><sentence text="Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate."><entity charOffset="27-36" id="DDI-PubMed.16416302.s1.e0" text="macrolide" /><entity charOffset="97-109" id="DDI-PubMed.16416302.s1.e1" text="testosterone" /><pair ddi="false" e1="DDI-PubMed.16416302.s1.e0" e2="DDI-PubMed.16416302.s1.e0" /><pair ddi="false" e1="DDI-PubMed.16416302.s1.e0" e2="DDI-PubMed.16416302.s1.e1" /></sentence><sentence text="Macrolide antibiotics are mechanism-based inactivators of CYP3A enzymes that exhibit varying degrees of inhibitory potency" /><sentence text=" Our aim was to predict quantitatively the drug-drug interaction (DDI) potential of five macrolides from in vitro studies using testosterone as the CYP3A substrate, and to compare the predictions generated from human liver microsomal and recombinant CYP3A4 data"><entity charOffset="128-140" id="DDI-PubMed.16416302.s3.e0" text="testosterone" /></sentence><sentence text="" /><sentence text="The in vitro kinetic constants of CYP3A inactivation (K (I) and k (inact)) were estimated by varying the time of pre-incubation and the concentration of troleandomycin, erythromycin, clarithromycin, roxithromycin or azithromycin"><entity charOffset="153-167" id="DDI-PubMed.16416302.s5.e0" text="troleandomycin" /><entity charOffset="169-181" id="DDI-PubMed.16416302.s5.e1" text="erythromycin" /><entity charOffset="183-197" id="DDI-PubMed.16416302.s5.e2" text="clarithromycin" /><entity charOffset="199-212" id="DDI-PubMed.16416302.s5.e3" text="roxithromycin" /><entity charOffset="216-228" id="DDI-PubMed.16416302.s5.e4" text="azithromycin" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e0" e2="DDI-PubMed.16416302.s5.e0" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e0" e2="DDI-PubMed.16416302.s5.e1" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e0" e2="DDI-PubMed.16416302.s5.e2" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e0" e2="DDI-PubMed.16416302.s5.e3" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e0" e2="DDI-PubMed.16416302.s5.e4" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e1" e2="DDI-PubMed.16416302.s5.e1" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e1" e2="DDI-PubMed.16416302.s5.e2" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e1" e2="DDI-PubMed.16416302.s5.e3" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e1" e2="DDI-PubMed.16416302.s5.e4" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e2" e2="DDI-PubMed.16416302.s5.e2" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e2" e2="DDI-PubMed.16416302.s5.e3" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e2" e2="DDI-PubMed.16416302.s5.e4" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e3" e2="DDI-PubMed.16416302.s5.e3" /><pair ddi="false" e1="DDI-PubMed.16416302.s5.e3" e2="DDI-PubMed.16416302.s5.e4" /></sentence><sentence text=" CYP3A activity was determined from the measurement of testosterone 6beta-hydroxylation with human liver microsomes (HLM) and recombinant CYP3A4 as the enzyme sources"><entity charOffset="55-67" id="DDI-PubMed.16416302.s6.e0" text="testosterone" /></sentence><sentence text=" The mechanism-based pharmacokinetic model was fitted with inactivation data to predict the increase in oral area under the plasma concentration-time curve (AUC) for midazolam" /><sentence text="" /><sentence text="All five macrolides inactivated testosterone 6beta-hydroxylation by HLM and recombinant CYP3A4 with k (inact) values in the range of 0"><entity charOffset="32-44" id="DDI-PubMed.16416302.s9.e0" text="testosterone" /></sentence><sentence text="023 to 0" /><sentence text="058 min(-1)" /><sentence text=" The potency of inactivation (K (I)) was higher using recombinant CYP3A4 as the enzyme source" /><sentence text=" The oral AUCs for midazolam were predicted from HLM data to increase 16" /><sentence text="6, 5" /><sentence text="3, 4" /><sentence text="6, 1" /><sentence text="6 and 1" /><sentence text="2-fold due to the inhibition of metabolic clearance by troleandomycin, erythromycin, clarithromycin, roxithromycin and azithromycin, respectively"><entity charOffset="55-69" id="DDI-PubMed.16416302.s18.e0" text="troleandomycin" /><entity charOffset="71-83" id="DDI-PubMed.16416302.s18.e1" text="erythromycin" /><entity charOffset="85-99" id="DDI-PubMed.16416302.s18.e2" text="clarithromycin" /><entity charOffset="101-114" id="DDI-PubMed.16416302.s18.e3" text="roxithromycin" /><entity charOffset="119-131" id="DDI-PubMed.16416302.s18.e4" text="azithromycin" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e0" e2="DDI-PubMed.16416302.s18.e0" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e0" e2="DDI-PubMed.16416302.s18.e1" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e0" e2="DDI-PubMed.16416302.s18.e2" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e0" e2="DDI-PubMed.16416302.s18.e3" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e0" e2="DDI-PubMed.16416302.s18.e4" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e1" e2="DDI-PubMed.16416302.s18.e1" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e1" e2="DDI-PubMed.16416302.s18.e2" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e1" e2="DDI-PubMed.16416302.s18.e3" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e1" e2="DDI-PubMed.16416302.s18.e4" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e2" e2="DDI-PubMed.16416302.s18.e2" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e2" e2="DDI-PubMed.16416302.s18.e3" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e2" e2="DDI-PubMed.16416302.s18.e4" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e3" e2="DDI-PubMed.16416302.s18.e3" /><pair ddi="false" e1="DDI-PubMed.16416302.s18.e3" e2="DDI-PubMed.16416302.s18.e4" /></sentence><sentence text=" These results are within the range of the AUC ratios reported for clinical DDI studies" /><sentence text=" The predicted AUC increases generated using recombinant CYP3A4 overestimated the magnitude of the DDIs" /><sentence text="" /><sentence text="The DDI potential of five macrolide antibiotics was quantitatively predicted from in vitro studies using testosterone as the CYP3A substrate with HLM as the enzyme source"><entity charOffset="105-117" id="DDI-PubMed.16416302.s22.e0" text="testosterone" /></sentence><sentence text="" /></document>